EcoDrugPlus


Keyword(s):	Surfactants
Molecule Category	Free-form

Keyword(s):

Surfactants

Molecule Category

Free-form


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70


InChI Key	FYMRMBOQEJEAKI-UHFFFAOYSA-N
Smiles	OCCOCCOCCOCCOCCOCCOCCOCCN(C)CCOCCOCCOCCOCCOCCOCCOCCO
InChI	InChI=1S/C33H69NO16/c1-34(2-6-37-10-14-41-18-22-45-26-30-49-32-28-47-24-20-43-16-12-39-8-4-35)3-7-38-11-15-42-19-23-46-27-31-50-33-29-48-25-21-44-17-13-40-9-5-36/h35-36H,2-33H2,1H3

InChI Key

FYMRMBOQEJEAKI-UHFFFAOYSA-N

Smiles

OCCOCCOCCOCCOCCOCCOCCOCCN(C)CCOCCOCCOCCOCCOCCOCCOCCO

InChI

InChI=1S/C33H69NO16/c1-34(2-6-37-10-14-41-18-22-45-26-30-49-32-28-47-24-20-43-16-12-39-8-4-35)3-7-38-11-15-42-19-23-46-27-31-50-33-29-48-25-21-44-17-13-40-9-5-36/h35-36H,2-33H2,1H3

Property Name	Value
Molecular Formula	C33H69NO16
Molecular Weight	735.46
AlogP	-0.86
Hydrogen Bond Acceptor	17.0
Hydrogen Bond Donor	2.0
Number of Rotational Bond	46.0
Polar Surface Area	172.92
Molecular species	None
Aromatic Rings	0.0
Heavy Atoms	50.0

Property Name

Value

Molecular Formula

C33H69NO16

Molecular Weight

735.46

AlogP

-0.86

Hydrogen Bond Acceptor

17.0

Hydrogen Bond Donor

2.0

Number of Rotational Bond

46.0

Polar Surface Area

172.92

Molecular species

None

Aromatic Rings

0.0

Heavy Atoms

50.0

Resources	Reference
NORMAN SUSDAT

Resources

Reference

NORMAN SUSDAT


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

AMINES, TALLOW, 8+8 EO (R=CH3)

Structure

Physicochemical Descriptors

Cross References